Skip to main content

Day: January 3, 2023

GoLogiq and GammaRey Sign Definitive Share Exchange Agreement for $320 Million Merger of the Two Fintech Companies

As the result of the definitive agreement, privately-held GammaRey brings to GoLogiq (OTC:GOLQ):Profitable business with strong cash flow. Nearly $800 million in customer financial assets. Full-stack fintech ecosystem designed for the New World Digital Economy, including a commodity-backed digital currency, digital wallet, and proprietary transaction platform for securities, goods and services. Pipeline of accretive and/or technology-enabling acquisitions.NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) — GoLogiq, Inc. (OTC:GOLQ), a U.S.-based global provider of fintech and consumer data analytics, has signed a definitive share exchange agreement with GammaRey, Inc., a privately-held fintech ecosystem for the New World Digital Economy.   Under the now definitive terms of the proposed agreement announced in December, GammaRey has merged...

Continue reading

Ackroo completes acquisition of Simpliconnect

Ackroo closes their second US based acquisition and their twelfth to date HAMILTON, Ontario, Jan. 03, 2023 (GLOBE NEWSWIRE) — Ackroo Inc. (TSX-V: AKR; OTC: AKRFF) (the “Company”), a loyalty marketing, payments and point-of-sale technology and services provider, through its’ wholly-owned subsidiary Ackroo Canada Inc., is pleased to announce that it has completed the acquisition of the Simpliconnect business. Simpliconnect is a US based SaaS provider focused on driving client engagement for small to medium sized convenience store and petroleum chains, specifically focused on chains with 2-100 sites/locations. Under the terms of the acquisition, Ackroo acquired all customer contracts and related IP of Simpliconnect adding over 60 clients and 350 locations. In consideration for the acquisition, the Company has paid $750,000 USD...

Continue reading

Molecular Farming Company Moolec Science Starts Trading on Nasdaq After Successful Closing of Business Combination

Moolec Science Ltd. and LightJump Acquisition Corporation closed their business combination agreement on December 30, 2022, resulting in Moolec UK and LightJump becoming wholly-owned subsidiaries of Moolec Science SA. Moolec Science will start trading on Nasdaq Capital Markets today under the tickers “MLEC” and “MLECW” for its common shares and warrants, respectively. Moolec Science is a category creator in the alternative protein ecosystem using Molecular Farming, a disruptive technology producing animal proteins within plants.LUXEMBOURG, Jan. 03, 2023 (GLOBE NEWSWIRE) — Moolec Science Ltd., a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming (“Moolec UK”), and LightJump Acquisition Corporation, a publicly traded special purpose acquisition company (“LightJump”),...

Continue reading

Targa Resources Corp. to Acquire Blackstone Energy Partners’ 25% Interest in Grand Prix NGL Pipeline for $1.05 Billion

HOUSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) — Targa Resources Corp. (NYSE: TRGP) (“Targa” or the “Company”) announced today a definitive agreement to acquire Blackstone Energy Partners’ (“Blackstone”) 25 percent interest in Targa’s Grand Prix NGL Pipeline (“Grand Prix”) for $1.05 billion in cash plus customary working capital adjustments. Targa will own 100 percent of Grand Prix upon closing. Grand Prix has capacity to transport up to one million barrels per day of natural gas liquids (“NGL”) to the NGL market hub at Mont Belvieu, Texas. Grand Prix connects Targa’s gathering and processing positions throughout the Permian Basin, North Texas, and Southern Oklahoma (as well as third-party positions) to Targa’s fractionation and storage complex at Mont Belvieu. The acquisition price represents approximately 8.75...

Continue reading

AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend that AVEO Stockholders Vote “FOR” the Transaction BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) — AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO’s Special Meeting of Stockholders (the “Special Meeting”) “FOR” the adoption of the Agreement and Plan of Merger among LG Chem, Ltd. (“LG Chem”), a subsidiary of LG Chem and AVEO (the “merger agreement”). Subject to the terms and conditions of the merger agreement, including obtaining requisite AVEO stockholder approval at the Special Meeting, LG Chem will acquire AVEO for merger consideration of $15.00 per share in cash. The Special...

Continue reading

Watsco Boosts Annual Dividend 11% to $9.80 Per Share

49th Consecutive Year of Paying Dividends MIAMI, Jan. 03, 2023 (GLOBE NEWSWIRE) — Watsco, Inc.’s (NYSE: WSO) Board of Directors has declared a regular quarterly cash dividend of $2.45 on each outstanding share of its Common and Class B common stock payable on January 31, 2023 to shareholders of record at the close of business on January 17, 2023. Watsco has paid dividends to shareholders for 49 consecutive years. The Company’s philosophy is to share increasing amounts of cash flow through higher dividends while maintaining a conservative balance sheet with continued capacity to build its distribution network. Future changes in dividends are considered in light of investment opportunities, cash flow, general economic conditions and Watsco’s overall financial condition. About Watsco Watsco is the largest distribution network for...

Continue reading

Anfield to Acquire Marysvale and Calf Mesa Uranium Projects in Utah

VANCOUVER, British Columbia, Jan. 03, 2023 (GLOBE NEWSWIRE) — Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or “the Company”) is pleased to announce that it has entered into a definitive agreement with Nedeel LLC & BBL-2 LLC (“the Sellers”) to acquire a 100% interest in 65 unpatented mining claims and historical data of the Marysvale uranium project, located in Beaver County, Utah, and 100% interest in 26 unpatented mining claims and historical data of the Calf Mesa uranium project, located in Emery County, Utah. Corey Dias, Anfield’s CEO commented: “We are pleased to secure additional claims near our Utah projects, including the Shootaring Canyon Mill, and will continue to seek out prospective assets which fit into our two-fold strategy of acquiring both near term and longer-term uranium and vanadium...

Continue reading

Great Elm Group Sells a Majority Interest in Forest Investments, Inc. to an Affiliate of JPMorgan Chase & Co.

The sale of a majority of its ownership interest in Forest Investments, Inc. is expected to ultimately raise approximately $45 million of cash on Great Elm Group’s Balance Sheet, enhancing its ability to focus exclusively on Investment Management. WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Great Elm Group, Inc. (“we,” “us,” “our,” “GEG” or “Great Elm,”) (NASDAQ: GEG), an investment management company, today announced its sale of a majority of its ownership interest in Forest Investments, Inc. (“Forest”) to J.P. Morgan Broker-Dealer Holdings Inc. (“JPM”). Transaction HighlightsGEG has sold 61% of its direct and indirect common equity of Forest to JPM for approximately $18 million in cash. Together with its purchase of 20% of the common equity of Forest in December 2020, JPM owns 81% of Forest as of December 30, 2022. GEG...

Continue reading

Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01

COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01. In November 2022, the Company submitted an Investigational New Drug Application (“IND”) along with a Fast Track designation application to the FDA for a Phase 2b clinical trial of EVX-01 in combination with KEYTRUDA® for the treatment of patients with metastatic melanoma. On December 22, 2022, the FDA issued approval for the Company to proceed with its Phase 2b trial. The Company anticipates a response to the Fast Track designation submission in the first quarter...

Continue reading

First Tellurium Closes Third and Final Tranche of Private Placement, Engages IR Consultant and Grants Stock Options

THIS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, BC, Canada, Jan. 03, 2023 (GLOBE NEWSWIRE) — First Tellurium Corp. (CSE: FTEL, OTC FSTTF) (the “Company” or “First Tellurium”) announces it has closed the third and final tranche (the “Third Tranche“) of a non-brokered private placement (the “Offering”) previously announced on October 16, 2022. The Company has issued 1,250,000 units for gross proceeds of $125,000. Together with the first tranche closing announced November 17, 2022 for $404,000 (comprised of 2,600,000 flow-through shares at a price of $0.14 for proceeds of $364,000 and 400,000 units at $0.10 per unit for proceeds of $40,000), the second tranche closing of announced December 20, 2022 for $986,600 (comprised of 150,000 flow-through...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.